Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alba Therapeutics (Larazotide Acetate Assets)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of assets related to a drug ingredient for celiac disease. The portfolio is comprised of assets relating to arazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 100 International Drive 23rd Floor
  • Suite 1040
  • Baltimore, MD 21202
  • United States

Alba Therapeutics (Larazotide Acetate Assets) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Alba Therapeutics (Larazotide Acetate Assets)‘s full profile, request access.

Request full access to PitchBook

Alba Therapeutics (Larazotide Acetate Assets) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Alba Therapeutics (Larazotide Acetate Assets)‘s full profile, request access.

Request full access to PitchBook